BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) is a sarcoma with a poor prognosis. A clinical trial, SARC028, revealed that treatment with anti-PD-1 drugs was effective against UPS. Studies have reported that UPS expresses PD-L1, sometimes strongly (≥ 50%). However, the mechanism of PD-L1 expression in UPS has remained unclear. CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) was identified as a novel regulator of PD-L1 expression. The positive relationship between PD-L1 and CMTM6 has been reported in several studies. The aim of this study was thus to examine CMTM6 expression in UPS and evaluate the relationship between PD-L1 and CMTM6 in this disease. MATERIALS AND METHODS: Fifty-one primary UPS samples were subjected to CMTM6 and PD-L1 immunostaining. CMTM6 expression was assessed using proportion and intensity scores. CMTM6 gene copy number was also evaluated using a real-time PCR-based copy number assay. We also analyzed the mRNA expression and copy number variation of PD-L1 and CMTM6 in The Cancer Genome Atlas (TCGA) data. RESULTS: TCGA data indicated that the mRNAs encoded by genes located around 3p22 were coexpressed with CMTM6 mRNA in UPS. Both proportion and intensity scores of CMTM6 positively correlated with strong PD-L1 expression (≥ 50%) (both p = 0.023). CMTM6 copy number gain increased CMTM6 expression. Patients with UPS with a high CMTM6 intensity score had a worse prognosis for overall survival. CONCLUSIONS: UPS showed variation in CMTM6 copy number and CMTM6 expression. CMTM6 expression was significantly correlated with PD-L1 expression, especially with strong PD-L1 expression.
BACKGROUND:Undifferentiated pleomorphic sarcoma (UPS) is a sarcoma with a poor prognosis. A clinical trial, SARC028, revealed that treatment with anti-PD-1 drugs was effective against UPS. Studies have reported that UPS expresses PD-L1, sometimes strongly (≥ 50%). However, the mechanism of PD-L1 expression in UPS has remained unclear. CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) was identified as a novel regulator of PD-L1 expression. The positive relationship between PD-L1 and CMTM6 has been reported in several studies. The aim of this study was thus to examine CMTM6 expression in UPS and evaluate the relationship between PD-L1 and CMTM6 in this disease. MATERIALS AND METHODS: Fifty-one primary UPS samples were subjected to CMTM6 and PD-L1 immunostaining. CMTM6 expression was assessed using proportion and intensity scores. CMTM6 gene copy number was also evaluated using a real-time PCR-based copy number assay. We also analyzed the mRNA expression and copy number variation of PD-L1 and CMTM6 in The Cancer Genome Atlas (TCGA) data. RESULTS: TCGA data indicated that the mRNAs encoded by genes located around 3p22 were coexpressed with CMTM6 mRNA in UPS. Both proportion and intensity scores of CMTM6 positively correlated with strong PD-L1 expression (≥ 50%) (both p = 0.023). CMTM6 copy number gain increased CMTM6 expression. Patients with UPS with a high CMTM6 intensity score had a worse prognosis for overall survival. CONCLUSIONS: UPS showed variation in CMTM6 copy number and CMTM6 expression. CMTM6 expression was significantly correlated with PD-L1 expression, especially with strong PD-L1 expression.
Authors: Jon Zugazagoitia; Yuting Liu; Maria Toki; John McGuire; Fahad Shabbir Ahmed; Brian S Henick; Richa Gupta; Scott N Gettinger; Roy S Herbst; Kurt A Schalper; David L Rimm Journal: J Thorac Oncol Date: 2019-10-09 Impact factor: 15.609
Authors: Kurt A Schalper; Daniel Carvajal-Hausdorf; Joseph McLaughlin; Mehmet Altan; Vamsidhar Velcheti; Patricia Gaule; Miguel F Sanmamed; Lieping Chen; Roy S Herbst; David L Rimm Journal: Clin Cancer Res Date: 2016-07-20 Impact factor: 12.531
Authors: Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel Journal: Lancet Oncol Date: 2017-10-04 Impact factor: 41.316
Authors: Emily Z Keung; Melissa Burgess; Ruth Salazar; Edwin R Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; Steven Attia; Richard F Riedel; James Hu; Scott H Okuno; Dennis A Priebat; Sujana Movva; Lara E Davis; Damon R Reed; Alexandre Reuben; Christina L Roland; Denise Reinke; Alexander J Lazar; Wei-Lien Wang; Jennifer A Wargo; Hussein A Tawbi Journal: Clin Cancer Res Date: 2020-01-03 Impact factor: 12.531
Authors: Marian L Burr; Christina E Sparbier; Yih-Chih Chan; James C Williamson; Katherine Woods; Paul A Beavis; Enid Y N Lam; Melissa A Henderson; Charles C Bell; Sabine Stolzenburg; Omer Gilan; Stuart Bloor; Tahereh Noori; David W Morgens; Michael C Bassik; Paul J Neeson; Andreas Behren; Phillip K Darcy; Sarah-Jane Dawson; Ilia Voskoboinik; Joseph A Trapani; Jonathan Cebon; Paul J Lehner; Mark A Dawson Journal: Nature Date: 2017-08-16 Impact factor: 49.962
Authors: Riccardo Mezzadra; Chong Sun; Lucas T Jae; Raquel Gomez-Eerland; Evert de Vries; Wei Wu; Meike E W Logtenberg; Maarten Slagter; Elisa A Rozeman; Ingrid Hofland; Annegien Broeks; Hugo M Horlings; Lodewyk F A Wessels; Christian U Blank; Yanling Xiao; Albert J R Heck; Jannie Borst; Thijn R Brummelkamp; Ton N M Schumacher Journal: Nature Date: 2017-08-16 Impact factor: 49.962
Authors: Sandra Martinez-Morilla; Jon Zugazagoitia; Pok Fai Wong; Harriet M Kluger; David L Rimm Journal: Oncoimmunology Date: 2020-12-29 Impact factor: 8.110
Authors: Simone Punt; Shruti Malu; Jodi A McKenzie; Soraya Zorro Manrique; Elien M Doorduijn; Rina M Mbofung; Leila Williams; Deborah A Silverman; Emily L Ashkin; Ana Lucía Dominguez; Zhe Wang; Jie Qing Chen; Sourindra N Maiti; Trang N Tieu; Chengwen Liu; Chunyu Xu; Marie-Andrée Forget; Cara Haymaker; Jahan S Khalili; Nikunj Satani; Florian Muller; Laurence J N Cooper; Willem W Overwijk; Rodabe N Amaria; Chantale Bernatchez; Timothy P Heffernan; Weiyi Peng; Jason Roszik; Patrick Hwu Journal: Cancer Immunol Immunother Date: 2020-10-29 Impact factor: 6.968